Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) reported a year-over-year drop in fourth-quarter 2012 net income to 374 million euros, from 397 million euros, with earnings per share falling to 0.45 euros, from 0.48 euros a year before. Quarterly core earnings per share, however, improved to 1.00 euros, from 0.97 euros in 2011.
On the other hand, excluding special items, adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA of 1.83 billion euros, were 18.4% higher than last year's 1.54 billion euros, with earnings before interest and taxes, or EBIT, growing 16.9% to 735 million euros, from 629 million euros.
Sales of the Bayer Group reached 9.86 billion euros, up 7.3% from 9.19 billion euros in the previous year.
For 2013, Bayer sees currency- and portfolio-adjusted sales growth between 4 and 5 percent, corresponding to Group sales of nearly 41 billion euros. Further, the Group plans to increase EBITDA before special items by a mid-single-digit percentage and core earnings per share by a high-single-digit percentage.
The company's Chief Executive Marijn Dekkers explained, "Bayer is also optimistic for its further development, thanks mainly to its innovative life-science products. The company therefore has ambitious aspirations for the period through 2015." Bayer nonetheless plans to respond to the commoditization of the business via further efficiency measures that should contribute 1.5 percentage points to the EBITDA margin before special items by 2015.
by RTT Staff Writer
For comments and feedback: email@example.com